APA (7th ed.) Citation

SA, W., MR, L., JC, K., EC, S., A, N., LM, S., . . . A, B. (2026). Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): A single-centre, open-label, phase 1b trial. The Lancet. Oncology, 27(5), 580. https://doi.org/10.1016/S1470-2045(26)00059-8

Chicago Style (17th ed.) Citation

SA, Wander, et al. "Safety and Antitumour Activity of Ipatasertib Combined with Endocrine Therapy and a CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer (TAKTIC): A Single-centre, Open-label, Phase 1b Trial." The Lancet. Oncology 27, no. 5 (2026): 580. https://doi.org/10.1016/S1470-2045(26)00059-8.

MLA (9th ed.) Citation

SA, Wander, et al. "Safety and Antitumour Activity of Ipatasertib Combined with Endocrine Therapy and a CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer (TAKTIC): A Single-centre, Open-label, Phase 1b Trial." The Lancet. Oncology, vol. 27, no. 5, 2026, p. 580, https://doi.org/10.1016/S1470-2045(26)00059-8.